CN113943363B - 一种肿瘤抑制肽 - Google Patents

一种肿瘤抑制肽 Download PDF

Info

Publication number
CN113943363B
CN113943363B CN202111155175.6A CN202111155175A CN113943363B CN 113943363 B CN113943363 B CN 113943363B CN 202111155175 A CN202111155175 A CN 202111155175A CN 113943363 B CN113943363 B CN 113943363B
Authority
CN
China
Prior art keywords
amino acid
polypeptide
endostatin
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111155175.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN113943363A (zh
Inventor
刘宏利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hep Pharmaceutical Co ltd
Original Assignee
Shanghai Hep Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hep Pharmaceutical Co ltd filed Critical Shanghai Hep Pharmaceutical Co ltd
Priority to CN202111155175.6A priority Critical patent/CN113943363B/zh
Publication of CN113943363A publication Critical patent/CN113943363A/zh
Application granted granted Critical
Publication of CN113943363B publication Critical patent/CN113943363B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202111155175.6A 2015-07-27 2016-07-21 一种肿瘤抑制肽 Active CN113943363B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111155175.6A CN113943363B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2015104467474 2015-07-27
CN201510446747 2015-07-27
PCT/CN2016/090800 WO2017016430A1 (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN201680044076.1A CN107922475B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155175.6A CN113943363B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680044076.1A Division CN107922475B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽

Publications (2)

Publication Number Publication Date
CN113943363A CN113943363A (zh) 2022-01-18
CN113943363B true CN113943363B (zh) 2023-11-28

Family

ID=57883958

Family Applications (17)

Application Number Title Priority Date Filing Date
CN202111155175.6A Active CN113943363B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN201680044076.1A Active CN107922475B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155262.1A Active CN113943365B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152258.XA Active CN113717275B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152272.XA Active CN113717278B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111151032.8A Active CN113717274B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152259.4A Active CN113717276B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155543.7A Active CN113980119B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153255.8A Pending CN115433267A (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152378.XA Active CN113912705B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153309.0A Active CN115433269B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155244.3A Active CN114031683B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153273.6A Active CN115433268B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152268.3A Active CN113717277B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153334.9A Active CN115433270B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155210.4A Active CN113943364B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155546.0A Active CN113980120B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽

Family Applications After (16)

Application Number Title Priority Date Filing Date
CN201680044076.1A Active CN107922475B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155262.1A Active CN113943365B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152258.XA Active CN113717275B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152272.XA Active CN113717278B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111151032.8A Active CN113717274B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152259.4A Active CN113717276B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155543.7A Active CN113980119B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153255.8A Pending CN115433267A (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152378.XA Active CN113912705B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153309.0A Active CN115433269B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155244.3A Active CN114031683B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153273.6A Active CN115433268B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111152268.3A Active CN113717277B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111153334.9A Active CN115433270B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155210.4A Active CN113943364B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽
CN202111155546.0A Active CN113980120B (zh) 2015-07-27 2016-07-21 一种肿瘤抑制肽

Country Status (5)

Country Link
US (1) US10351613B2 (enExample)
EP (1) EP3330285B1 (enExample)
JP (1) JP6903633B2 (enExample)
CN (17) CN113943363B (enExample)
WO (1) WO2017016430A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113943363B (zh) * 2015-07-27 2023-11-28 上海贺普药业股份有限公司 一种肿瘤抑制肽
CN113244370A (zh) * 2020-02-13 2021-08-13 珠海市藤栢医药有限公司 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途
CN115991739B (zh) * 2021-12-20 2023-10-20 珠海市藤栢医药有限公司 一种抗肿瘤的多肽及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2537179A1 (en) * 2003-08-29 2005-03-10 Children's Medical Center Corporation Anti-angiogenic peptides from the n-terminus of endostatin
CN102924578A (zh) * 2011-08-09 2013-02-13 哈药集团技术中心 抗肿瘤多肽及其制备方法和抗肿瘤应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
EP0857210B1 (en) * 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6174861B1 (en) * 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
US6825167B1 (en) * 2000-04-03 2004-11-30 Regents Of The University Of Minnesota Genetic modification of endostatin
CN1239516C (zh) * 2002-02-08 2006-02-01 中国医学科学院基础医学研究所 肿瘤坏死因子相关细胞凋亡诱导配体胞外区突变多肽及其制法与用途
WO2003074551A2 (en) * 2002-03-01 2003-09-12 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
US7078485B2 (en) * 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
CN1875104A (zh) * 2003-08-29 2006-12-06 儿童医学中心公司 来自内皮抑素n－末端的抗血管生成肽
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
CN101062954A (zh) * 2006-05-16 2007-10-31 中国人民解放军军事医学科学院野战输血研究所 具有抗血管生成作用的融合蛋白及其编码基因与应用
CN100586961C (zh) * 2006-05-16 2010-02-03 中国人民解放军军事医学科学院野战输血研究所 对肿瘤细胞具有抑制作用的融合蛋白及其编码基因与应用
WO2008125635A1 (en) * 2007-04-11 2008-10-23 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
CN101096671A (zh) * 2007-06-01 2008-01-02 徐寒梅 血管生成抑制剂hm-x及其制备方法和应用
JP2010531666A (ja) * 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ 抗体−エンドスタチン融合タンパク質及びそのバリアント
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
CN113943363B (zh) * 2015-07-27 2023-11-28 上海贺普药业股份有限公司 一种肿瘤抑制肽

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2537179A1 (en) * 2003-08-29 2005-03-10 Children's Medical Center Corporation Anti-angiogenic peptides from the n-terminus of endostatin
CN102924578A (zh) * 2011-08-09 2013-02-13 哈药集团技术中心 抗肿瘤多肽及其制备方法和抗肿瘤应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A 27-Amino-Acid Synthetic Peptide Corresponding to the NH2-Terminal Zinc-Binding Domain of Endostatin Is Responsible for Its Antitumor Activity;Robert M. Tjin Tham Sjin et al;Cance Res;第65卷(第9期);第3656-3663页 *

Also Published As

Publication number Publication date
CN115433268A (zh) 2022-12-06
CN113717278A (zh) 2021-11-30
CN114031683A (zh) 2022-02-11
CN115433269B (zh) 2025-10-17
CN115433267A (zh) 2022-12-06
EP3330285A4 (en) 2019-01-09
CN113980120B (zh) 2024-06-04
CN113717277A (zh) 2021-11-30
CN113943364B (zh) 2024-02-02
CN114031683B (zh) 2023-12-26
CN115433269A (zh) 2022-12-06
CN113717275A (zh) 2021-11-30
CN115433270A (zh) 2022-12-06
EP3330285A1 (en) 2018-06-06
JP2018526987A (ja) 2018-09-20
CN113717275B (zh) 2024-02-02
CN113717278B (zh) 2024-02-02
CN107922475B (zh) 2021-08-27
CN115433268B (zh) 2025-10-03
CN113943365A (zh) 2022-01-18
CN107922475A (zh) 2018-04-17
CN113980119B (zh) 2024-05-28
CN115433270B (zh) 2025-10-14
US20190010201A1 (en) 2019-01-10
CN113943363A (zh) 2022-01-18
CN113943364A (zh) 2022-01-18
CN113980119A (zh) 2022-01-28
EP3330285B1 (en) 2022-08-31
CN113717274B (zh) 2023-11-28
CN113980120A (zh) 2022-01-28
JP6903633B2 (ja) 2021-07-14
WO2017016430A1 (zh) 2017-02-02
CN113912705B (zh) 2023-12-22
US10351613B2 (en) 2019-07-16
CN113717274A (zh) 2021-11-30
CN113717277B (zh) 2024-02-02
CN113717276B (zh) 2024-02-02
CN113717276A (zh) 2021-11-30
CN113912705A (zh) 2022-01-11
CN113943365B (zh) 2023-12-08

Similar Documents

Publication Publication Date Title
EP2283028A2 (en) Vegfr-1/nrp-1 targeting peptides
CN113943363B (zh) 一种肿瘤抑制肽
US20200062811A1 (en) Yap protein inhibiting polypeptide and application thereof
CN112442129A (zh) 肿瘤酶响应型重组焦亡蛋白递药系统及其抗肿瘤用途
CN108295244B (zh) 用于治疗乳腺肿瘤的多肽
CN108864258A (zh) 具有抑制肿瘤功能的peg化多肽及其制备方法与应用
CN108299556B (zh) 一种治疗血液肿瘤的多肽

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant